Molecular signatures of intrahepatic cholangiocarcinoma: role in targeted therapy selection

被引：0
|
作者：
Glushko, Tetiana [1 ]
Costello, James [1 ]
Chima, Ranjit [1 ]
McGettigan, Melissa [1 ]
Kim, Richard [1 ]
Jeong, Daniel [1 ]
Qayyum, Aliya [1 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Dept Radiol, 2902 USF Magnolia Dr, Tampa, FL 33612 USA
来源：
EUROPEAN JOURNAL OF RADIOLOGY | 2025年 / 187卷
关键词：
BILIARY-TRACT CANCER; MUTATIONS; CHEMOTHERAPY; ARID1A; MULTICENTER; EXPRESSION; PROGNOSIS; SURVIVAL; FEATURES; PATHWAY;
D O I：
10.1016/j.ejrad.2025.112056
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
Cholangiocarcinoma is a highly lethal disease with a 5-year overall survival rate of 7-20%. A minority of patients present with resectable disease, and relapse rates remain high. Emerging data from next generation sequencing analysis have identified various actionable mutations which drive the different disease courses opening door to precision medicine and targeted therapies. This review focuses on the clinical significance of genetic alterations as well as the role of systemic therapies, immunotherapy and targeted therapies for intrahepatic cholangiocarcinoma.
引用
收藏
页数：28
相关论文
共 50 条
  • [1] Intrahepatic cholangiocarcinoma: Evolving role of neoadjuvant and targeted therapy
    Ghio, Michael
    Vijay, Adarsh
    ANNALS OF HEPATO-BILIARY-PANCREATIC SURGERY, 2023, 27 (02) : 123 - 130
  • [2] Molecular targeted and systemic therapy for intrahepatic cholangiocarcinoma: a multi-disciplinary approach
    Merath, Katiuscha
    Tiwari, Ankur
    Parikh, Alexander A.
    Pawlik, Timothy M.
    FUTURE ONCOLOGY, 2023, 19 (39) : 2607 - 2621
  • [3] Molecular heterogeneity in intrahepatic cholangiocarcinoma
    Ahn, Keun Soo
    Kang, Koo Jeong
    WORLD JOURNAL OF HEPATOLOGY, 2020, 12 (12) : 1148 - 1157
  • [4] Molecular biology of cholangiocarcinoma and its implications for targeted therapy in patient management
    Gilbert, T. M.
    Randle, L.
    Quinn, M.
    Mcgreevy, O.
    O'leary, L.
    Young, R.
    Diaz-Neito, R.
    Jones, R. P.
    Greenhalf, B.
    Goldring, C.
    Fenwick, S.
    Malik, H.
    Palmer, D. H.
    EJSO, 2025, 51 (02):
  • [5] The role of microRNAs in intrahepatic cholangiocarcinoma
    Li, Zheng
    Shen, Jianxiong
    Chan, Matthew T. V.
    Wu, William Ka Kei
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2017, 21 (01) : 177 - 184
  • [6] Association of BRAF Variants With Disease Characteristics, Prognosis, and Targeted Therapy Response in Intrahepatic Cholangiocarcinoma
    Xin, Hao-Yang
    Sun, Rong-Qi
    Zou, Ji-Xue
    Wang, Peng-Cheng
    Wang, Jia-Yin
    Ye, Yu-Hang
    Liu, Kai-Xuan
    Hu, Zhi-Qiang
    Zhou, Zheng-Jun
    Fan, Jia
    Zhou, Jian
    Zhou, Shao-Lai
    JAMA NETWORK OPEN, 2023, 6 (03) : E231476
  • [7] Narrative review: current management and novel targeted therapies in intrahepatic cholangiocarcinoma
    Bath, Natalie M.
    Pawlik, Timothy M.
    CHINESE CLINICAL ONCOLOGY, 2023, 12 (01)
  • [8] Targeted mutation-based therapy for intrahepatic cholangiocarcinoma
    Yang, Facai
    Qiu, Yinghe
    Yi, Bin
    HEPATOMA RESEARCH, 2023, 9
  • [9] Challenges and opportunities for treating intrahepatic cholangiocarcinoma: targeted therapy
    Gim, Gahyun
    Badri, Nabeel
    HEPATOMA RESEARCH, 2023, 9
  • [10] Intrahepatic Cholangiocarcinoma: A Summative Review of Biomarkers and Targeted Therapies
    Acher, Alexandra W.
    Paro, Alessandro
    Elfadaly, Ahmed
    Tsilimigras, Diamantis
    Pawlik, Timothy M.
    CANCERS, 2021, 13 (20)
12345